Erratum: Stakeholder assessment of the evidence for cancer genomic tests: Insights from three case studies (Genetics in Medicine (2012) 14 (656-662) DOI: 10.1038/gim.2012.3);Stakeholder assessment of the evidence for cancer genomic tests: Insights from three case studies

Genetics in Medicine

Volumn 14, Issue 7, 2012, Pages 656-662

  Deverka, Patricia A ^a   Schully, Sheri D ^b   Ishibe, Naoko ^b   Carlson, Josh J ^c   Freedman, Andrew ^b   Goddard, Katrina A B ^d   Khoury, Muin J ^b,e   Ramsey, Scott D ^f  

^a Center for Medical Technology Policy   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d CENTER FOR HEALTH RESEARCH   (United States)

^e NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

Author keywords

EGFR testing; evidence based decision making; genomic testing; Lynch syndrome; Oncotype DX; stakeholder engagement

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER GENETICS; CANCER PROGNOSIS; CLINICAL DECISION MAKING; FEMALE; GENE MUTATION; GENETIC SCREENING; GENOMICS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MEDICAL RESEARCH; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; RECEPTOR GENE; REIMBURSEMENT; SCREENING TEST; VALIDITY; WORKSHOP;

EID: 84863709801     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2012.99     Document Type: Erratum

References (27)

1. Feero WG, Guttmacher AE, Collins FS. Genomic medicine-an updated primer. N Engl J Med 2010;362(21):2001-2011.
2. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007;9:665-674. (Pubitemid 350287151)
3. Schully SD, Benedicto CB, Gillanders EM, Wang SS, Khoury MJ. Translational research in cancer genetics: the road less traveled. Public Health Genomics 2011;14:1-8.
4. Institute of Medicine (IOM). Generating Evidence for Genomic Diagnostic Test Development-Workshop Summary. http://www.iom.edu/Home/Reports/2011/ Generating-Evidence-for-Genomic-Diagnostic-Test-Development.aspx. Accessed 20 July 2011.
5. DeStefano F, Whitehead N, Lux LJ, Lohr KN. Infrastructure to Monitor Utilization and Outcomes of Gene-Based Applications: An Assessment. May 2008. http://www.effectivehealthcare.ahrq.gov/index.cfm/search-forguides-reviews-and- reports/?pageaction=displayproduct&productID=89. Accessed 23 November 2011.
6. Sun F, Bruening W, Erinof E, Schoelles KM. Addressing Challenges in Genetic Test Evaluation: Evaluation Frameworks and Assessment of Analytic Validity. http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides- reviews-and-reports/?pageaction=displayproduct&produ ctID=704. Accessed 23 November 2011.
7. Tunis SR, Benner J, McClellan M. Comparative effectiveness research: Policy context, methods development and research infrastructure. Stat Med 2010;29:1963-1976.
8. National Cancer Institute (NCI). Comparative Effectiveness Research in Genomics and Personalized Medicine. http://cancercontrol.cancer.gov/od/phg/ research.asp?type=CER. Retrieved 20 July 2011.
9. Lauer MS, Collins FS. Using science to improve the nation's health system: NIH's commitment to comparative effectiveness research. JAMA 2010;303:2182-2183.
10. Centers for Medicare & Medicaid Services (CMS). MEDCAC Meeting 2/25/2009-Genetic (Genomic) Testing. http://www.cmms.hhs.gov/medicare-coverage- database/details/medcac-meeting-details.aspx? MEDCACId=47&NCAId= 224&NcaName=Pharmacogenomic+Testing+for+ Warfarin+Response&NCDId= 333&ncdver=1&IsPopup=y&bc=AAAAAAAA IAAA&. Accessed 20 July 2011.
11. Ishibe N, Schully S, Freedman A, Ramsey SD. Use of Oncotype DX in Women with Node-Positive Breast Cancer. PLoS Curr 2011;3:RRN1249.
12. Ishibe N, Schully S, Freedman AN, Ramsey SD. Use of Oncotype DX in Women with Node-Positive Breast Cancer. PLoS Currents: Evidence on Genomic Tests 2011. http://knol.google.com/k/naoko-ishibe/use-ofoncotype-dx-in-women-with-node/ 3c272etk8k4of/6.
13. PLoS. PLoS Currents: Evidence on Genomic Tests. http://knol.google.com/k/ plos/plos-currents-evidence-on-genomic-tests/28qm4w0q65e4w/50#. Accessed 20 July 2011.
14. SurveyMonkey. Privacy Policy. http://www.surveymonkey.com/privacypolicy. aspx. Accessed 20 July 2011.
15. Meridia. Audience Response System. http://www.meridiaars.com/products/ keypad-system-for-purchase.php. Accessed 20 July 2011.
16. Veenstra DL, Roth JA, Garrison LP Jr, Ramsey SD, Burke W. A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med 2010;12: 686-693.
17. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734. (Pubitemid 46622311)
18. EGAPP. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med 2009;11(1):66-73.
19. Harris L, Fritsche H, Mennel R, et al.; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312. (Pubitemid 350232263)
20. TEC B. Gene expression profiling of breast cancer to select women for adjuvant chemotherapy. Technol Eval Cent Asses Program Exec Summ 2008;22(13):1-8.
21. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121-2127.
22. Gridelli C, Ardizzoni A, Douillard JY, et al. Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer 2010;68:319-331.
23. National Comprehensive Cancer Network (NCCN) (2011). http://www. nccn.org/professionals/physician-gls/pdf/breast.pdf.
24. Goddard KAB, Knaus WA, Whitlock E, et al. Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med 2012, this issue.
25. Khoury MJ, Feero WG, Reyes M, et al.; GAPPNet Planning Group. The genomic applications in practice and prevention network. Genet Med 2009;11:488-494.
26. Institute of Medicine (IOM). Clinical Practice Guidelines We Can Trust. http://www.iom.edu/Reports/2011/Clinical-Practice-Guidelines-We-Can-Trust. aspx. Retrieved 17 August 2011.
27. Clancy C, Collins FS. Patient-Centered Outcomes Research Institute: the intersection of science and health care. Sci Transl Med 2010;2:37cm18.